Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

NCT ID: NCT01204164

Last Updated: 2016-05-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2016-04-30

Brief Summary

This is a multicenter, open-label, dose escalation Phase 1 study.

Detailed Description

This is a multicenter, open-label, dose escalation, Phase 1/1b study.

For Parts 1, 2, and 3 of the study, the primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with different types of hematological malignancy.

For Part 4, the primary objective is to evaluate the safety and tolerability of once-weekly dosing at the maximum-tolerated dose/ Recommended Phase 2 Dose of TG02 in combination with carfilzomib.

This study consists of four parts:

• Part 1: single agent TG02 in acute leukemia patients
• Part 2: single agent TG02 in multiple myeloma patients
• Part 3: TG02 in combination with carfilzomib in multiple myeloma patients
• Part 4: TG02 in combination with carfilzomib in carfilzomib refractory multiple myeloma patients.

Conditions

AML; ALL; Blast Crisis; MDS; Multiple Myeloma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TG02 in AL

Single agent TG02 citrate in acute leukemia patients

Group Type: EXPERIMENTAL

TG02 citrate

Intervention Type: DRUG

TG02 citrate capsules given orally.

TG02 in MM

Single Agent TG02 citrate in multiple myeloma patients

Group Type: EXPERIMENTAL

TG02 citrate

Intervention Type: DRUG

TG02 citrate capsules given orally.

TG02 + CFZ in MM

TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients

Group Type: EXPERIMENTAL

TG02 citrate

Intervention Type: DRUG

TG02 citrate capsules given orally.

Carfilzomib

Intervention Type: DRUG

Carfilzomib per PI

TG02 + CFZ + DEX in CFZ refractory MM

TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients

Group Type: EXPERIMENTAL

TG02 citrate

Intervention Type: DRUG

TG02 citrate capsules given orally.

Carfilzomib

Intervention Type: DRUG

Carfilzomib per PI

Dexamethasone

Intervention Type: DRUG

Dexamethasone (Oral or IV)

Interventions

TG02 citrate

TG02 citrate capsules given orally.

Intervention Type: DRUG

Carfilzomib

Carfilzomib per PI

Intervention Type: DRUG

Dexamethasone

Dexamethasone (Oral or IV)

Intervention Type: DRUG

Other Intervention Names

No other names.; Kyprolis; Ozurdex, Maxidex, Decadron, Baycadron

Eligibility Criteria

Inclusion Criteria

• Relapsed AML, ALL, CML in blast crisis, or MDS
• 65+ yrs with AML not eligible for standard frontline chemo
• Interval from prior treatment to time of study drug at least 5 half-lives for cytotoxic/ noncytotoxic agents.
• Persistent clinically significant toxicities from prior chemo ≤ Grd 1
• ECOG PS 0-2
• Lab values:

• Cr ≤ 2X ULN
• ALT and/or AST ≤2.5 X ULN
• Total bilirubin ≤1.5 X ULN unless considered due to Gilbert's syndrome
• Negative pregnancy test
• Can take oral med

• Relapsed multiple myeloma. At least ≥1 line of therapy and progressed after ≥1 prior therapy
• Measurable disease defined as at least one of the following:

• Serum M ≥500 mg/dL
• Urine M ≥200 mg per 24hr
• Involved FLC ≥10 mg/dL and abnormal FLC ratio in serum (<0.26 or >1.65)
• Measurable soft tissue plasmacytoma
• Persistent clinically significant toxicities from prior chemo ≤ Grd 1
• ECOG PS 0-2
• Lab values:

• ANC of >1000/mm3
• Platelets ≥50,000/mm3
• Cr ≤2X the ULN
• ALT and/or AST ≤2.5X ULN
• Total bilirubin ≤1.5X ULN, unless considered due to Gilbert's syndrome
• Negative pregnancy test
• Can take oral med

• Measurable disease defined as at least one of the following:

• Serum M ≥500 mg/dL
• Urine M protein ≥200 mg per 24hr
• Involved FLC level ≥10 mg/dL and abnormal FLC ratio in serum (<0.26 or >1.65)
• Meet at least one of the criteria below:

• a. ≥2 prior therapies including proteasome inhibitor and immunomodulatory agent (IMiD)
• b. ≥1 prior therapy and one of the following abnormalities: 17p del, p53, 1q amp, 1p del, t(4;14)
• Interval from prior treatment to time of study drug at least 5 half-lives or 3 wks, which ever is shorter, for noncytotoxic agents
• Persistent clinically significant toxicities from prior chemo ≤ Grd 1 or Grd 2 neuropathy without pain
• ECOG PS 0-2
• Lab values:

• ANC of >1000/mm3 independent of G-CSF
• Platelets ≥50,000/mm3 independent of transfusion
• MDRD calculated or measured CrCl of ≥30 mL/min
• ALT and/or AST ≤3X ULN
• Total bilirubin ≤2X ULN, unless considered due to Gilbert's syndrome
• Negative pregnancy test
• Can take oral med

• Measurable disease defined as at least one of the following:

• Serum M ≥500 mg/dL
• Urine M protein ≥200 mg per 24hr
• Involved FLC level ≥10 mg/dL and an abnormal FLC ratio in serum (<0.26 or >1.65)
• Received prior therapies including:

• a. bortezomib
• b. an IMiD
• c. carfilzomib. Demonstrated disease progression on or within 60d of completion of carfilzomib therapy
• Interval from prior treatment to time of study drug at least 5 half-lives or 3 wks, which ever is shorter, for noncytotoxic agents.
• Persistent clinically significant toxicities from prior chemo ≤ Grd 1, or Grd 2 neuropathy without pain.
• ECOG PS 0-2
• Lab values:

• ANC of >1000/mm3 independent of G-CSF
• Platelets ≥50,000/mm3 independent of transfusion
• MDRD calculated or measured CrCl of ≥30 mL/min
• ALT and/or AST ≤3X ULN
• Total bilirubin ≤2X ULN, unless considered due to Gilbert's syndrome
• Negative pregnancy test
• Can take oral med

Exclusion Criteria

• Previous allogenic hematopoietic transplant within 90 d
• Concurrent severe or uncontrolled medical disease that would compromise the safety or compromise the ability of the patient to complete the study
• Prolonged QTC interval >450ms
• Symptomatic CNS metastases
• Known HIV or AIDS
• Actively treated for a second malignancy
• Pregnant or nursing women

• Multiple myeloma of IgM subtype, POEMS, plasma cell leukemia
• Corticosteroids discontinued ≥7 days of initiating therapy
• Previous chemo within 2 wks
• Hx of ventricular arrhythmia or symptomatic conduction abnormality within 12m
• CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, myocardial infarction within 6m
• Prolonged QTc interval (males >450ms, females >470ms)
• Previous allogeneic hematopoietic transplant within 90 days of study enrollment, Active GVHD requiring treatment.
• Concurrent severe or uncontrolled medical disease that would compromise the safety or compromise the ability of the patient to complete the study
• Symptomatic CNS metastases
• Known HIV or AIDS
• Prior or 2nd malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with PSA of less than or equal to 0.1 ng/ml), or other cancer for which the subject has received curative therapy at least 3 yrs prior to study entry
• Treatment-related MDS
• Significant neuropathy (Grd 3-4 or Grd 2 with pain) at the time of 1st dose
• Primary AL amyloidosis
• Pleural effusions requiring thoracentesis or ascites requiring paracentesis
• Pregnant or nursing women

• Multiple myeloma of IgM subtype, POEMS, plasma cell leukemia
• Previous chemo within 2 wks
• Hx ventricular arrhythmia or symptomatic conduction abnormality within 12m
• CHF, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, and myocardial infarction within 6m
• Prolonged QTc interval (males >450ms, females >470ms)
• Previous allogeneic hematopoietic transplant within 90 days. Active GVHD requiring treatment
• Concurrent severe or uncontrolled medical disease that would compromise the safety or compromise the ability of the patient to complete study
• Symptomatic CNS metastases
• Known HIV or AIDS
• Prior or 2nd malignancy, except non-melanoma skin cancer, completely resected cervical or prostate cancer (with PSA of less than or equal to 0.1 ng/ml), or other cancer for which the subject has received curative therapy at least 3 yrs prior to study entry
• Treatment-related MDS
• Significant neuropathy (Grd 3-4 or Grd 2 with pain) at the time of 1st dose
• Primary AL amyloidosis
• Pleural effusions requiring thoracentesis or ascites requiring paracentesis
• Pregnant or nursing women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tragara Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

T Parrott

Role: STUDY_DIRECTOR

Tragara Pharmaceuticals

Locations

RMCC

Denver, Colorado, United States

Emory

Atlanta, Georgia, United States

Rush

Chicago, Illinois, United States

IU

Indianapolis, Indiana, United States

HUMC

Hackensack, New Jersey, United States

Cornell

New York, New York, United States

OSU

Columbus, Ohio, United States

SCRI

Nashville, Tennessee, United States

MDACC

Houston, Texas, United States

Countries

United States

Other Identifiers

TG02-101

Identifier Type: -

Identifier Source: org_study_id